We are live on
!
Find out more
UOC
UBS O'Connor Portfolio holdings
AUM
$3.76B
1-Year Est. Return
62.41%
This Fund
S&P 500
This Quarter
Est. Return
+7.76%
1 Year Est. Return
+62.41%
3 Year Est. Return
+179.84%
5 Year Est. Return
+371.69%
10 Year Est. Return
+1,534.25%
AUM
$4.75B
AUM Growth
+$529M
(+13%)
Cap. Flow
+$146M
Cap. Flow
% of AUM
3.08%
Top 10 Holdings %
Top 10 Hldgs %
47.97%
Holding
745
New
128
Increased
150
Reduced
259
Closed
162
Avg Time Held Equity + Options
3.8
quarters
Top 10 Avg Time Held Equity + Options
1.1
quarters
Top 20 Avg Time Held Equity + Options
1.1
quarters
Avg Time Held Equity only
3.9
quarters
Top 10 Avg Time Held Equity only
1.1
quarters
Top 20 Avg Time Held Equity only
1.1
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$253M |
| 2 |
PDCE
PDC Energy, Inc.
PDCE
|
+$210M |
| 3 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$206M |
| 4 |
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
|
+$135M |
| 5 |
LSI
Life Storage, Inc.
LSI
|
+$87.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
First Horizon
FHN
|
+$179M |
| 2 |
AQUA
Evoqua Water Technologies Corp. Common Stock
AQUA
|
+$146M |
| 3 |
PRVB
Provention Bio, Inc. Common Stock
PRVB
|
+$70.5M |
| 4 |
Tower Semiconductor
TSEM
|
+$50.8M |
| 5 |
XM
Qualtrics International Inc. Class A Common Stock
XM
|
+$45.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 32.35% |
| 2 | Technology | 15.68% |
| 3 | Financials | 11.99% |
| 4 | Miscellaneous | 10.5% |
| 5 | Real Estate | 8.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
276
OrthoPediatrics
KIDS
$565M
| $1.98M | 0.04% |
45,219
-4,427
| -9% | -$204K |
2022 Q1
5 quarters
|
|
277
Dyne Therapeutics
DYN
$3.11B
| $1.98M | 0.04% |
175,752
-849
| -0.5% | -$10K |
2022 Q1
5 quarters
|
|
|
FRBN
278
DELISTED
Forbion European Acquisition Corp. Class A Ordinary Shares
FRBN
| $1.94M | 0.04% |
181,263
-4,086
| -2% | -$43.3K |
2022 Q2
4 quarters
|
|
279
DELISTED
Integrated Wellness Acquisition Corp
WEL
| $1.94M | 0.04% |
181,263
-4,086
| -2% | -$43.5K |
2022 Q1
5 quarters
|
|
280
DELISTED
HCM Acquisition Corp Class A Ordinary Shares
HCMA
| $1.93M | 0.04% |
181,263
-4,086
| -2% | -$43K |
2022 Q1
5 quarters
|
|
281
ArcBest
ARCB
$2.89B
| $1.93M | 0.04% |
+19,540
| New | +$1.75M |
2023 Q2
0 quarters
|
|
282
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $1.93M | 0.04% |
262,265
+32,265
| +14% | +$244K |
2023 Q1
1 quarter
|
|
283
PUT
Nabors Industries
NBR
$1.23B
| $1.92M | 0.04% |
33,700
-8,200
| -20% | -$833K |
2023 Q1
1 quarter
|
|
284
DELISTED
Ventyx Biosciences
VTYX
| $1.92M | 0.04% |
58,463
+11,437
| +24% | +$394K |
2022 Q3
3 quarters
|
|
285
Roivant Sciences
ROIV
$25.6B
| $1.92M | 0.04% |
190,211
+28,386
| +18% | +$254K |
2022 Q4
2 quarters
|
|
286
DELISTED
National Storage Affiliates Trust
NSA
| $1.91M | 0.04% |
54,981
-109,779
| -67% | -$4.14M |
2021 Q2
8 quarters
|
|
287
Zurn Elkay Water Solutions
ZWS
$7.72B
| $1.91M | 0.04% |
+70,891
| New | +$1.61M |
2023 Q2
0 quarters
|
|
288
Micron Technology
MU
$1.16T
| $1.89M | 0.04% |
30,000
| – | – |
2023 Q1
1 quarter
|
|
|
ARYE
289
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
| $1.88M | 0.04% |
181,263
-4,086
| -2% | -$42.1K |
2022 Q1
5 quarters
|
|
290
Agios Pharmaceuticals
AGIO
$1.9B
| $1.88M | 0.04% |
66,221
+13,721
| +26% | +$341K |
2022 Q4
2 quarters
|
|
291
Tarsus Pharmaceuticals
TARS
$3.42B
| $1.87M | 0.04% |
103,262
+5,087
| +5% | +$80.9K |
2022 Q3
3 quarters
|
|
292
Protagonist Therapeutics
PTGX
$9.3B
| $1.85M | 0.04% |
67,094
-41,379
| -38% | -$1.04M |
2022 Q1
5 quarters
|
|
|
VRNA
293
DELISTED
Verona Pharma
VRNA
| $1.85M | 0.04% |
87,628
-9,944
| -10% | -$212K |
2022 Q3
3 quarters
|
|
294
DELISTED
Enphys Acquisition Corp.
NFYS
| $1.85M | 0.04% |
178,033
-4,013
| -2% | -$41.3K |
2022 Q2
4 quarters
|
|
295
Axsome Therapeutics
AXSM
$8.82B
| $1.85M | 0.04% |
25,735
+3,169
| +14% | +$234K |
2022 Q1
5 quarters
|
|
296
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $1.84M | 0.04% |
56,528
+17,046
| +43% | +$622K |
2022 Q1
5 quarters
|
|
297
PTC Therapeutics
PTCT
$5.4B
| $1.83M | 0.04% |
45,101
-9,662
| -18% | -$473K |
2022 Q4
2 quarters
|
|
298
DELISTED
RAPT Therapeutics
RAPT
| $1.81M | 0.04% |
12,102
+596
| +5% | +$92.8K |
2022 Q2
4 quarters
|
|
299
DELISTED
Concord Acquisition Corp II
CNDA
| $1.81M | 0.04% |
176,330
-3,974
| -2% | -$40.6K |
2021 Q4
6 quarters
|
|
300
Procept Biorobotics
PRCT
$1.05B
| $1.81M | 0.04% |
51,116
+9,173
| +22% | +$303K |
2022 Q4
2 quarters
|
|
Similar funds
FNBT
ACI
RC
A
CGL
CB
JCM
MPM
UBS O'Connor's Q2 2023 Portfolio in Review
As of Q2 2023, UBS O'Connor held 745 positions worth $4.75B, up 13% from $4.22B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
UBS O'Connor deployed $146M of net new capital in Q2 2023, opening 128 new positions and adding to 150 existing holdings. Its largest new stake was PDC Energy, Inc.: 3,101,445 shares worth $221M.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 21% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Tower Semiconductor, an estimated $50.8M trimmed.
- UBS O'Connor's largest Q2 2023 buy was PDC Energy, Inc.: 3,101,445 shares worth $221M.
- UBS O'Connor added most to Seagen Inc. Common Stock in Q2 2023, an estimated $253M increase.
- UBS O'Connor's biggest Q2 2023 reduction was Tower Semiconductor, cutting an estimated $50.8M.
- UBS O'Connor fully exited First Horizon in Q2 2023, selling an estimated $179M.
- UBS O'Connor's ten largest holdings make up 48% of its $4.75B portfolio in Q2 2023.
- UBS O'Connor opened 128 new positions and closed 162 in Q2 2023.
- UBS O'Connor's portfolio value rose 13% quarter-over-quarter to $4.75B.
Based on UBS O'Connor's 13F filing for Q2 2023, filed 14 Aug 2023.